abstract |
The present invention provides a pharmaceutical composition comprising a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for SSEA4, a population of engineered cells expressing said CAR, and said genetically modified cells expressing said CAR do. The pharmaceutical composition may be for use in the treatment of said cancer in a subject suffering from such cancer wherein at least a partial population of cancerous cells of the cancer express SSEA4. |